Sotyktu (deucravacitinib) / BMS - LARVOL DELTA

Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update. (PubMed, Pharmacol Res) - "Seven drugs (abrocitinib, baricitinib, deucravacitinib, deuruxolitinib, ritlecitinib, tofacitinib, upadacitinib) are prescribed for the management of inflammatory diseases (atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, and ulcerative colitis)...The following four drugs received FDA approval in 2024 - deuruxolitinib (alopecia areata), ensartinib and lazertinib (non-small cell lung cancer), and tovorafenib (pediatric glioma) while mirdametinib was approved in 2025 for the treatment of type I neurofibromatosis (von Recklinghausen disease). Apart from netarsudil, temsirolimus, and trilaciclib, the approved protein kinase blockers are orally bioavailable. This article summarizes the physicochemical properties of all 85 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, ligand efficiency, lipophilic efficiency, polar surface area, and solubility. A total of 39 of the 85..."

FDA event • Journal • Review • Alopecia • Atopic Dermatitis • Brain Cancer • Chronic Myeloid Leukemia • CNS Tumor • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Glioma • Hematological Malignancies • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Leukemia • Lung Cancer • Neurofibromatosis • Non Small Cell Lung Cancer • Oncology • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Solid Tumor • Ulcerative Colitis • MAP2K1

'RF - New treatments in cutaneous lupus erythematosus: current and future perspectives". (PubMed, Actas Dermosifiliogr) - No abstract available

Journal • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=261 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed

Trial completion • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Rapid Clinical Improvement With Tyrosine Kinase 2 Inhibitor Deucravacitinib in Overlapping Psoriasis and Atopic Dermatitis. (PubMed, Int J Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • TYK2

ART26.12, A FATTY ACID-BINDING PROTEIN 5 INHIBITOR, SHOWS EFFICACY IN PRECLINICAL PSORIASIS MODELS. (PubMed, J Invest Dermatol) - "In vivo, ART26.12 (25 or 100 mg/kg BID) or BMS-986165 (TYK2 inhibitor; 10 mg/kg QD) were given orally for 10 days in the imiquimod mouse model. Lipidomic analysis showed widespread modulation including ceramides and linoleic acid derivatives. These data suggest ART26.12 may be a potential psoriasis treatment."

Journal • Preclinical • Dermatology • Immunology • Inflammation • Psoriasis • FABP5 • IL17A • IL22 • TYK2

Not Available (PubMed, Arerugi) - No abstract available

Journal

Computational insights of deucravacitinib's selectivity for TYK2 pseudokinase vs. JAK kinase domain via molecular modeling studies. (PubMed, J Biomol Struct Dyn) - "The interaction with the hydrophobic catalytic region caused the ATP-binding site to adopt a closed conformation, thereby minimizing protein movement at the glycine loop of the JAK pseudokinase protein. In summary, our study holds significant potential for informing the strategic design of TYK2 inhibitors with enhanced affinity."

Journal • Dermatology • Immunology • Psoriasis • JAK1 • JAK2 • JAK3 • TYK2

Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System. (PubMed, Int J Clin Pharm) - "Our study confirms the known AEs associated with deucravacitinib and identifies several potential AEs. These findings provide preliminary safety data for the practical use of deucravacitinib."

Adverse events • Journal • Real-world evidence • Acne Vulgaris • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Musculoskeletal Pain • Pain • Psoriasis • Urticaria • Varicella Zoster • TYK2

TYPP: TYK2 Inhibition in Paradoxical Psoriasis (clinicaltrials.gov) - P2/3 | N=2 | Terminated | Sponsor: Prof Curdin Conrad | N=26 ➔ 2 | Trial completion date: Aug 2025 ➔ Mar 2025 | Not yet recruiting ➔ Terminated | Trial primary completion date: Aug 2025 ➔ Mar 2025; External research funds were canceled, so study could unforunately not be continued

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Dermatology • Immunology • Psoriasis

Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System (ISPOR 2025) - "Deucravacitinib presented the lowest cost-per-response ratio amongst all treatments available for moderate to severe plaque psoriasis in the Brazilian private"

Dermatology • Immunology • Inflammation • Psoriasis

Pharmacological Management of Psoriasis: Current Landscape and Future Perspectives. (PubMed, Recent Adv Inflamm Allergy Drug Discov) - "Numerous novel synthetic agents, such as JAK/STAT inhibitors [ruxolitinib, peficitinib], TYK2 inhibitors [zasocitinib, ropsacitinib], RORꝩT inhibitors [cedirogant], A3AR agonists [piclodenoson], and CXCR2 antagonists [vimnerixin] are undergoing extensive clinical trials and have demonstrated beneficial outcomes in multiple phases of these trials. Deucravacitinib, an orally administered TYK2 inhibitor, has recently received FDA approval for the treatment of moderate to severe plaque psoriasis...Moreover, these pathways can be exploited to personalize anti-psoriatic therapy, minimize side effects, and maximize therapeutic outcomes. Altogether, the integration of biological agents and synthetic agents can overcome the challenges associated with the management of the repertoire of psoriatic pathophysiology and symptoms."

Journal • Dermatology • Immunology • Inflammation • Psoriasis • CXCR2 • IL23A • TYK2

Successful treatment of subacute cutaneous lupus erythematosus with the TYK-2 inhibitor deucravacitinib in a patient with concomitant psoriasis vulgaris. (PubMed, J Dtsch Dermatol Ges) - No abstract available

Journal • Cutaneous Lupus Erythematosus • Dermatology • Immunology • Inflammatory Arthritis • Lupus • Psoriasis • TYK2

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis (clinicaltrials.gov) - P1 | N=1 | Active, not recruiting | Sponsor: University of Alabama at Birmingham | Recruiting ➔ Active, not recruiting | N=20 ➔ 1

Enrollment change • Enrollment closed • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis

Deucravacitinib POETYK PsA and PsO clinical study data (EULAR 2025) - "Sponsored by BMS."

Clinical

Impact of deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, on glucocorticoid use and flares in patients with active systemic lupus erythematosus: a post hoc analysis of the phase 2 PAISLEY trial (EULAR 2025) - No abstract available

Clinical • P2 data • Retrospective data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • TYK2

Investigating the impact of deucravacitinib treatment on cardiovascular risk-associated biomarkers in patients with systemic lupus erythematosus: results from the phase 2 PAISLEY study (EULAR 2025) - No abstract available

Biomarker • Clinical • P2 data • Cardiovascular • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

BMS - TYK-ing the Path Forward in PsA with deucravacitinib (EULAR 2025) - "Sponsored by BMS. Learning Objectives:1) Discuss treatment challenges and unmet needs in patients with PsA.2) Highlight the latest scientific updates in PsA.3) Review the rationale for targeting the TYK2 pathway in PsA.4) Present phase 3 PsA data and long-term PsO data from the deucravacitinib POETYK clinical programs."

TYK2

Impact of deucravacitinib treatment on cardiovascular risk–associated scores and biomarkers in patients with active psoriatic arthritis: results from a phase 2 trial (EULAR 2025) - No abstract available

Biomarker • Clinical • P2 data • Cardiovascular • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and safety of oral deucravacitinib in patients with cutaneous manifestations of lupus erythematosus: results from PAISLEY CLE, a global, randomized, placebo-controlled, phase 2 trial (EULAR 2025) - No abstract available

Clinical • P2 data • Immunology • Inflammatory Arthritis • Lupus

DEUCRAVACITINIB IN MODERATE TO SEVERE PLAQUE PSORIASIS: 5-YEAR, LONG-TERM SAFETY AND EFFICACY RESULTS FROM THE PHASE 3 POETYK PSO-1, PSO-2, AND LTE TRIALS (EULAR 2025) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Psoriasis

Efficacy and safety of deucravacitinib up to week 52 from POETYK PsA-2: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis (EULAR 2025) - No abstract available

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

ViTYK: Vitiligo Treatment by Targeting TYK2 Mediated Responses (clinicaltrials.gov) - P2 | N=128 | Recruiting | Sponsor: Centre Hospitalier Universitaire de Nice | Phase classification: P3 ➔ P2

Phase classification • Dermatology • Immunology • Vitiligo

Retrospective Real-World Study Assessing Treatment Patterns of Adult Patients with Moderate-to-Severe Psoriasis in the United States Initiating Advanced Therapies and Their Dispositions (ISPOR 2025) - "Several advanced therapies (ATs) including tumor necrosis factor (TNF) inhibitors, interleukin (IL) inhibitors (e.g., IL-12/23, IL-23, IL-17), apremilast, deucravacitinib and biosimilars of TNF-inhibitors and IL-12/23 inhibitors are indicated for the treatment of moderate-to-severe PsO in the US. Originator biologics and especially TNF-inhibitors originators were the predominant treatment choice for first-line moderate-to-severe psoriasis therapy. Half of the patients remained on first-line therapy for 8.5 months. The use of biosimilars was limited."

Metastases • Real-world • Real-world evidence • Retrospective data • Cardiovascular • Dermatology • Hypertension • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A • IL23A

Central TYK2 inhibition identifies TYK2 as a key neuroimmune modulator. (PubMed, Proc Natl Acad Sci U S A) - "We deployed brain-penetrant TYK2 inhibitors (cTYK2i) alongside the peripherally restricted TYK2 inhibitor (pTYK2i; BMS-986165) to untangle the contributions of central TYK2 inhibition in diverse models of neuroinflammation. Finally, we demonstrate TYK2 inhibition has a robust impact on a unique subset of activated astrocytes termed Interferon-Responsive-Reactive-Astrocytes (IRRA). The data presented herein identify a key role for CNS TYK2 signaling in regulating neuroinflammation and solidify TYK2 as a potential therapeutic target for MS."

Journal • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • TYK2

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials. (PubMed, Dermatol Ther (Heidelb)) - P3 | "Deucravacitinib did not result in clinically meaningful changes in laboratory parameters over 3 years, including changes seen with Janus kinase (JAK) 1,2,3 inhibitors. Grade ≥ 3 laboratory AEs and discontinuations were rare."

Journal • P3 data • Dermatology • Immunology • Psoriasis • TYK2